He has been recognised for his efforts in driving finance transformation, African expansion and systems integration at the pharmaceutical multinational
AstraZeneca CFO Osman Mia has been nominated for the CFO Awards 2018. This is Osman’s debut nomination. He has been recognised for his efforts in driving finance transformation, African expansion and systems integration at the pharmaceutical multinational.
- Register NOW for the 2018 CFO Awards.
The chartered accountant and University of KwaZulu-Natal graduate began his career in his hometown of Durban at PwC as an audit senior, before moving on to enjoy a fruitful tenure at Tetra Pak, working his way up from financial manager to controller and director and finally to Sub-Saharan Africa Cluster Leader in August 2006. He assumed the role of CFO at AstraZeneca South Africa and Sub-Saharan Africa in November 2013, leading the organisation’s financial awareness, budgeting and management of financial information, while also heading up the supply chain, IT, legal, procurement and SHE departments. Now based in London, he has moved on to a broader role in the firm’s international division.
The annual 'Oscars for South African CFOs', the CFO Awards recognise CFOs of listed companies, large corporations, state-owned entities and government institutions, and awards them for outstanding performance and leadership.
Osman was delighted with his nomination:
“I am extremely humbled and honoured by my nomination to the prestigious CFO Awards 2018. It is a victory in itself to get through the tough vetting process, but of course, I would like to win an award. Although I am based in London, I will certainly be present at the ceremony next year.”
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
